Precision therapeutic targeting of human cancer cell motility

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Cancer cell motility is a key driver of metastasis, organ damage, and mortality.
• Targeting cancer cell motility is challenging due to its complex regulatory mechanisms.

Purpose of the Study:

• To identify and synthesize small molecules that can selectively inhibit cancer cell motility.
• To evaluate the efficacy and mechanism of action of a novel compound, KBU2046, in preclinical cancer models.

Main Methods:

• High-throughput phenotypic screening of small molecules synthesized via efficient chemical routes.
• In vitro assays for cell motility and invasion.
• In vivo studies using murine models of prostate and breast cancer to assess metastasis, bone destruction, and survival.
• Molecular, cellular, and systemic-level assays to elucidate the mechanism of action.

Main Results:

• KBU2046 was identified as a potent inhibitor of cancer cell motility and invasion in vitro.
• KBU2046 significantly inhibited metastasis, reduced bone destruction, and prolonged survival in multiple preclinical cancer models.
• The compound demonstrated efficacy at nanomolar blood concentrations after oral administration.
• Mechanistic studies revealed KBU2046 selectively binds chaperone heterocomplexes, altering client protein binding involved in motility regulation without exhibiting classical chaperone inhibitor toxicity.

Conclusions:

• KBU2046 represents a novel, targeted therapeutic agent for inhibiting cancer cell motility and metastasis.
• The compound targets a unique regulatory mechanism of cell motility, distinct from classical chaperone inhibitors.
• KBU2046 shows significant therapeutic potential and provides a platform for future human studies.